Compare Citius Pharmaceuticals Inc (CTXR) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Norwegian Cruise Line Holdings Ltd trades at $18.93 (market cap $8.59B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 429.3× Citius Pharmaceuticals Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | NCLH | |
|---|---|---|
Market Cap | $20.01M | $8.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $26.94 |
52-Week Low | $0.48 | $14.79 |
Enterprise Value | $16.23M | $23.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
NCLH trades at $18.93, up 2.05% today, with a bearish technical signal but strong fundamentals including a P/E of 11.33 and net income margin of 7.49%. Recent Q2 2026 earnings beat expectations at $0.48 per share, though revenue growth faces headwinds from high costs. Analyst consensus is a buy with a $20.73 price target, but news highlights concerns over fuel expenses and demand.
The outlook is mixed: valuation metrics suggest upside potential, but risks from macroeconomic pressures and execution challenges persist. Investors may find opportunity if turnaround plans gain traction, yet volatility from operational costs and travel demand fluctuations warrants caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
